A complete probiotics group

Probi

Probi develops, produces, markets and sells probiotics globally to food, health and pharmaceutical companies. Probiotics are living microorganisms that have a beneficial effect on health when taken in a sufficient amount. The company's research focuses primarily on gastrointestinal health, immune systems, nutritional and iron intake and metabolic health. The Group is organized in two business areas - Consumer HealthCare and Functional Food.

Financials

PROBI

SEKm 2017 2018 2019
Sales 612 592 713
Sales growth (%) 38,1 -3,3 20,3
EBITDA 157 150 199
EBITDA margin (%) 25,7 25,3 27,9
EBIT adj 104 99 144
EBIT adj margin (%) 17 16,7 20,3
Pretax profit 92 94 142
EPS rep 6,35 6,37 9,7
EPS growth (%) -22,8 0,3 52,2
EPS adj 6,35 6,37 9,7
DPS 0 1,5 2
EV/EBITDA (x) 24,8 32,1 23,8
EV/EBIT adj (x) 37,4 48,8 32,8
P/E (x) 53,6 67,7 44,5
P/E adj (x) 53,6 67,7 44,5
EV/sales (x) 6,4 8,1 6,6
FCF yield (%) 3,1 2,3 2,1
Dividend yield (%) 0 0,3 0,5
Net IB debt/EBITDA 0,1 -0,6 -0,9